Dendritic Cells Contribute to Autoimmune Kidney Injury in MRL-*Fas^lpr* Mice

YASUNORI IWATA, KENGO FURUICHI, NORIHIKO SAKAI, HIROYUKI YAMAUCHI, YASUYUKI SHINOZAKI, HAIYAN ZHOU, YUKIE KUROKAWA, TADASHI TOYAMA, SHINJI KITAJIMA, TOSHIYA OKUMURA, SHINGO YAMADA, IKURO MARUYAMA, KOUJI MATSUSHIMA, SHUICHI KANEKO, and TAKASHI WADA

ABSTRACT. *Objective.* Dendritic cells (DC) contribute to autoimmune disease progression and pathogenesis. Mature DC have been reported to secrete high mobility group box protein (HMGB-1), a novel inflammatory cytokine, via p38 mitogen-activated protein kinase (MAPK) activation. We investigated whether DC are involved in progression of autoimmune diseases followed by secretion of HMGB-1 via p38 MAPK activation in a lupus-prone mouse model.

Methods. FR167653, a specific inhibitor of p38 MAPK, was given orally from 3 months of age in MRL-*Fas^lpr* mice. Cultured DC, treated with or without FR167653, were stimulated with tumor necrosis factor-α.

Results. Inhibition of p38 MAPK led to a reduction in the number of CD11c-positive cells, including those with the mature phenotype, in the diseased kidney and spleen, which resulted in improvement of kidney pathology in MRL-*Fas^lpr* mice. The number of CD11c-positive cells in circulation was also reduced. HMGB-1 protein and transcripts detected in the diseased kidney, and the number of cells dual-positive for HMGB-1 and CD11c, were reduced by inhibition of p38 MAPK. Maturation of cultured DC and increased cytokines, including HMGB-1, in the supernatant were inhibited by FR167653 treatment. These results suggest that DC are involved in the progression of autoimmune kidney diseases in MRL-*Fas^lpr* mice followed by HMGB-1 secretion via p38 MAPK activation.

Conclusion. Our results indicated that DC secrete HMGB-1 via p38 MAPK activation to participate in autoimmunity in MRL-*Fas^lpr* mice. (First Release Jan 15 2009; J Rheumatol 2009;36:306–14; doi:10.3899/ jrheum.080318)

Key Indexing Terms:
DENDRITIC CELLS   HMGB-1   p38 MAPK   KIDNEY
LUPUS MODEL MICE   ALARMINS

CD11c-positive dendritic cells (DC) are among the most potent antigen-presenting cells. Interaction between DC and T cells is essential for initiation of immune responses. Recent studies indicated that mature DC also influence proinflammatory responses[1,2]. Immature DC located in peripheral tissues can be induced to undergo phenotypic maturation by a variety of cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin 1ß (IL-1ß) through activation of some signal transduction pathways. In particular, p38 mitogen-activated protein kinase (MAPK) has been shown to play a critical role in the maturation of DC[3,4]. DC have been reported to play an important role in the pathogenesis and progression of autoimmune diseases, including kidney diseases[5-9].

High mobility group box protein (HMGB-1), which is a DNA-binding nuclear and cytosolic protein, shows inflammatory properties[10]. Recently, HMGB-1 has been classified as an alarmin, a group of proteins that provide early warning signals to activate innate and adaptive immune systems in response to infection or tissue injury[11,12]. HMGB-1 has been reported to be involved in the inflammatory processes

The Journal of Rheumatology 2009; 36:2; doi:10.3899/jrheum.080318

in autoimmune diseases, including rheumatoid arthritis[13,14] and Sjögren's syndrome[15]. HMGB-1 is secreted from mature DC as well as activated monocytes/macrophages (Mφ) in response to inflammatory stimuli, such as lipopolysaccharide (LPS) and proinflammatory cytokines[10]. Necrotic cells have also been reported to release HMGB-1. Released HMGB-1 induces activation of DC via p38 MAPK activation[16,17].

The autoimmune disease in MRL/MPJ-*lpr/lpr* (MRL-*Fas^lpr*) mice resembles human systemic lupus erythematosus, characterized by dysregulation of both cellular and humoral immunity[18]. This strain is particularly valuable as a model in which to investigate the pathogenesis of autoimmune kidney injury. Previously, we reported that inhibition of phosphorylation of p38 MAPK ameliorated kidney injury, resulting in prolonged survival in MRL-*Fas^lpr* mice, followed by reduction of cytokine/chemokine production in the kidneys[19].

We hypothesized that DC are involved in the progression of autoimmune diseases followed by production of HMGB-1 via p38 MAPK activation. In this study, we show that FR167653 (denoted FR), a p38 MAPK inhibitor, reduced the number of CD11c-positive cells as well as HMGB-1 in the diseased kidney. p38 MAPK inhibition also reduced HMGB-1 excretion from activated DC *in vitro*.

MATERIALS AND METHODS

Mice. MRL-*Fas^lpr* mice were obtained from Charles River Japan Inc., Atsugi, Japan. FR (32 mg/kg/day) dissolved in drinking water was administered orally from 3 months of age. Mice in any group were sacrificed at 6 months of age. Ten MRL/MpJ++ (MRL++) mice were used as negative controls. All procedures in the animal experiments complied with the Guideline for the Care and Use of Laboratory Animals of Kanazawa University.

Histopathology. Kidney. Kidneys were either snap-frozen in OCT compound for cryostat sectioning or fixed in 10% neutral-buffered formalin. Formalin-fixed tissue was embedded in paraffin, and 4-μm sections were stained with periodic acid-Schiff and evaluated by a light microscopy.

Antibodies. The following primary antibodies were used for immunostaining; biotin or fluorescein isothianate (FITC)-conjugated hamster anti-mouse CD11c antibody, FITC-conjugated hamster anti-mouse CD80 antibody, phycoerythrin (PE)-conjugated mouse anti-mouse I-A^k antibody (BD Biosciences, San Diego, CA, USA), FITC-conjugated rat anti-mouse CC chemokine receptor (CCR7) antibody (Abcam, Cambridge, UK), and rabbit anti-mouse HMGB-1 antibody (BD Biosciences). The secondary antibodies for immunofluorescence staining were streptavidin-PerCP-Cy5.5 conjugate (BD Biosciences). Rabbit anti-phosphorylated p38 MAPK polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to detect phosphorylated p38-positive cells.

Immunohistochemical examination. Tissues for immunoperoxidase staining were snap-frozen in OCT (Miles Scientific, Naperville, IL, USA) and stored at –80°C. CD11c and HMGB-1-positive lesions were examined using monoclonal antibodies (10 μg/ml, ×1000, respectively). These lesions were identified using the avidin-biotin complex technique or the Envision method (Dako, Glostrup, Denmark). In addition, phosphorylated p38 MAPK was evaluated within the kidneys. The presence of phosphorylated p38 MAPK was detected as described[19].

The positive area of CD11c and HMGB-1 was evaluated from the whole area of cortex and outer medulla in the complete sagittal kidney section, and expressed as a percentage/glomeruli or visual field using MacScope version 6.02.

Dual staining. To determine the phenotypes of CD11c-positive cells, dual-labeling immunofluorescence immunohistochemistry was performed. Briefly, sections were first incubated overnight with biotin- or FITC-conjugated anti-mouse CD11c antibody. After rinsing in phosphate buffered saline, streptavidin-PerCP-Cy5.5 conjugate was added for biotin-conjugated antibody. Then, FITC-conjugated anti-mouse CCR7 or FITC-conjugated anti-mouse CD80 antibody, or PE-conjugated anti-mouse I-A^k antibody was added, and the sections were incubated overnight. Adobe Photoshop (Adobe Systems, San Jose, CA, USA) was used for image handling, and the 3-color channels were handled separately.

Flow cytometric analysis. A single-cell suspension was obtained from spleens as described[20]. Following cell isolation, red blood cells were lysed using FACS lysis solution (BD Biosciences). Heparinized blood was collected from the tail vein of the mice. FITC- or allophycocyanin (APC)-conjugated hamster anti-mouse CD11c antibody, FITC-conjugated hamster anti-mouse CD80 antibody, biotin- or PE-conjugated mouse anti-mouse I-A^k antibody, and APC-conjugated rat anti-mouse CCR7 antibody (Biolegend, San Diego, CA, USA) were used for detection of cell-surface markers. To detect phosphorylated p38 MAPK, cells were fixed and permeabilized using BD Phosflow™ following the manufacturer's protocol (BD Biosciences). The cells were then stained with PE-conjugated anti-phospho-p38 MAPK antibody (BD Biosciences). The frequencies of cells expressing cell-surface markers were determined by analyzing a minimum of 10,000 cells using FlowJo software (Tree Star, Palo Alto, CA, USA).

Real-time reverse transcription-polymerase chain reaction (RT-PCR). To determine transcripts of HMGB-1, total RNA was extracted from the whole kidneys. Reverse transcription was performed as reported[19]. Quantitative real-time RT-PCR were performed on the ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA) using 384-well microtiter plates. Reactions were performed in a total volume of 20 μl, containing 1 μl of cDNA sample, TaqMan Gene Expression Assays, and TaqMan Universal PCR Master Mix (Applied Biosystems), using the universal temperature cycles. Assay identifiers of TaqMan Gene Expression Assays were Mm00801666_m1 for murine HMGB-1 and Mm00446953_m1 for murine ß-glucuronidase (GUS). The mRNA expression in each sample was finally described after correction with GUS expression.

Cell culture and treatment. Bone marrow-derived DC were prepared as described[21,22]. Briefly, bone marrow cells were suspended at 2×10^5 cells/ml in 10-mm dishes with RPMI-1640 medium supplemented with 10% fetal bovine serum with 20 ng/ml recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF; R&D Systems, Minneapolis, MN, USA) in a humidified atmosphere of 5% CO^2/95% air at 37°C. On Day 3, another 10 ml of this medium was added. On Days 6 and 8, half the culture supernatant was collected and centrifuged. The cell pellet was resuspended in 10 ml of fresh medium containing 20 ng/ml GM-CSF and returned to the original plate. On Day 10, CD11c cells were purified using MACS beads (Miltenyi Biotec, Auburn, CA, USA) following the manufacturer's protocol. Purified CD11c-positive cells were harvested for 24 h with or without FR167653 (1×10^{-6} M) in the presence of TNF-α (20 ng/ml; R&D Systems).

Detection of cytokines in supernatants of cultured DC by ELISA. HMGB-1 levels in the supernatants of cultured DC were determined using an HMGB-1 ELISA kit (Shino-Test, Sagamihara, Japan). IL-12 levels and IL-23 levels were analyzed using BD OptEIA™ mouse IL-12 (p40) ELISA Set and mouse IL-23 (p19/p40, IL23) ELISA Ready-Set-Go (eBioscience, San Diego, CA, USA), respectively. All analyses were performed according to the respective manufacturer's protocol.

Statistical analyses. The data represent means ± SEM. Statistical significance was determined by ANOVA and Kruskal-Wallis analyses.

RESULTS

Frequency of CD11c-positive cells, including mature phenotype, was increased according to disease activity in spleens of MRL-Fas^lpr mice. Flow cytometric analysis was performed to determine whether CD11c-positive cells contribute to the pathogenesis of MRL-*Fas^lpr* mice. The frequency of CD11c-positive cells was determined in splenocytes of MRL-*Fas^lpr* and MRL++ mice. The frequency of CD11c-positive cells was increased during disease progression (Figure 1). Moreover, the frequency of MHC class II, CD80, CCR7-positive mature phenotype was also increased in the spleens of MRL-*Fas^lpr* mice (Figure 1).

p38 MAPK activation contributed to maturation of CD11c-positive splenocytes. To determine the effect of p38 MAPK signaling on the maturation of DC, phosphorylation of p38 MAPK was analyzed by flow cytometry (Figure 2a). p38 MAPK-activated CD11c-positive cells included cells with the CCR7- and MHC class II-positive mature phenotypes (Figure 2b). In contrast, the frequencies of these mature phenotypes were reduced in the phosphorylated p38 MAPK-negative CD11c-positive population (Figure 2c).

Inhibition of p38 MAPK decreased infiltration of CD11c-positive cells, including those with mature phenotype, in kidneys of MRL-Fas^lpr mice. Phosphorylated p38-positive cells were detected in perivascular lesions (Figure 3a), and were decreased by administration of FR (Figure 3b), suggesting that p38 MAPK activation is involved in autoimmune kidney injury. Kidney pathology in untreated mice consisted of severe proliferative glomerulonephritis and interstitial/perivascular damage. In contrast, renal pathological changes were attenuated but not abrogated in FR-treated MRL-*Fas^lpr* mice, as compared to those of MRL++ mice[19]. CD11c-positive cells were detected in perivascular and periglomerular lesions in diseased kidneys (Figure 3c, 3d). The area of CD11c-positive cells, expressed as percentage/visual field, was examined by computer analysis. At 6 months of age, CD11c-positive cells were decreased to 4.6% ± 0.6% in treated mice, as compared to 13.0% ± 3.6% in untreated MRL-*Fas^lpr* mice (Figure 3c, 3g). To determine the presence of mature DC, dual immunofluorescence immunohistochemistry labeling for CD11c (Figure 3d) and CCR7 (Figure 3e) was performed. In untreated MRL-*Fas^lpr* mice, cells


Figure 1. The frequency of CD11c-positive cells was analyzed in splenocytes of MRL-Fas^lpr and MRL++ mice. The frequency of CD11c-positive cells was increased during disease progression. Moreover, the frequency of MHC class II, CD80, CCR7-positive mature phenotype was also increased in the spleen of MRL-Fas^lpr mice. Isotype control is shown in each analysis. The data are representative of more than 3 experiments.

Figure 2. (a) To determine the influence of p38 MAPK signaling on maturation of dendritic cells, phosphorylation of p38 MAPK was analyzed by flow cytometry. (b) p38 MAPK-activated CD11c-positive cells contained CCR7- and MHC class II-positive mature phenotypes. (c) In contrast, the frequencies of these mature phenotypes were reduced in the phosphorylated p38 MAPK-negative CD11c-positive population. Isotype control is shown in each analysis. Data are representative of more than 3 experiments.

dual-positive for CD11c and CCR7 were detected in perivascular lesions at 6 months of age (Figure 3f). In treated mice, the area of cells dual-positive for CD11c and CCR7 (Figure 3g) was decreased in comparison to untreated MRL-*Fas^lpr* controls (3.3% ± 0.2%, 10.7% ± 3.2%, respectively; $p < 0.05$). Moreover, the numbers of CD80- or MHC class II-positive CD11c-positive cells were also decreased in the FR-treated group (Figure 3g).

Inhibition of p38 MAPK decreased mature CD11c-positive cells in spleens of MRL-Fas^lpr mice. CD11c-positive cells were located in the T cell areas in the spleens of MRL-*Fas^lpr* mice at 6 months of age (Figure 4a, 4b). In treated MRL-*Fas^lpr* mice, CD11c-positive cell numbers tended to be reduced, but the difference was not significant in comparison to untreated controls (9.5% ± 1.7%, 10.9% ± 1.1%, respectively; Figure 4a, 4e). The area of cells with the mature phenotype dual-positive for CD11c (Figure 4b) and CCR7 (Figure 4c) was decreased as compared to untreated MRL-*Fas^lpr* mice at 6 months of age (7.9% ± 0.4%, 5.8% ± 0.3%, respectively, $p < 0.05$; Figure 4d, 4e). Moreover, the numbers of CD80- or MHC class II-positive CD11c-positive cells were also decreased in the FR-treated group (Figure 4e).

CD11c-positive cells were decreased by p38 MAPK inhibi-
tion in the circulation. Flow cytometric analysis was performed to evaluate the effect of the inhibition of p38 MAPK on circulating CD11c-positive cells. CD11c-positive cells were detected at a level of 9.9% ± 0.4% at 6 months of age. In mice treated with FR, CD11c-positive cell numbers in hemolyzed blood were reduced to 6.3% ± 0.6% in comparison to untreated MRL-*Fas^lpr* controls at 6 months of age (Figure 5a, 5b).

HMGB-1-positive area was reduced by p38 MAPK inhibition in kidneys. Immunohistochemical analysis was performed to investigate involvement of HMGB-1 in kidneys of MRL-*Fas^lpr* mice. The HMGB-1-positive area was expressed as the percentage/glomeruli or visual field by computer analysis. High levels of HMGB-1 expression were noted within the glomeruli as well as infiltrates of mononuclear cells in the interstitium (Figure 6a). HMGB-1-positive area was also detected in perivascular lesions in the diseased kidneys (Figure 6b). The percentages of HMGB-1-positive area were 11.3% ± 2.0% in glomeruli and 28.3% ± 3.5% in interstitium in untreated MRL-*Fas^lpr* mice at 6 months of age. Glomerular and interstitial HMGB-1-positive areas were reduced in treated MRL-*Fas^lpr* mice as compared to untreated controls (6.0% ± 1.0% and 13.3% ± 1.5%, respec-

Figure 3. (a) Phosphorylated p38-positive cells were detected in perivascular lesions in untreated MRL-*Fas^lpr* mice. (b) The number of phosphorylated p38-positive cells was decreased by inhibition of p38 MAPK. This result indicated that FR167653 inhibited p38 MAPK activation. (c, d) CD11c-positive cells were detected in perivascular and periglomerular lesions in the diseased kidneys. (e) CCR7-positive cells were located in the same lesions as CD11c-positive cells. (f) Cells dual-positive for CD11c and CCR7 were detected in perivascular lesions. Kidney pathology was determined by staining with the indirect avidin-biotinylated peroxidase complex method and dual-labeled immunofluorescence immunohistochemistry method (magnification ×200). (g) The number of CD11c-positive cells, expressed as percentage/visual field, was determined by computer analysis. In treated mice, the numbers of CD11c-positive cells and cells dual-positive for CD11c and CCR7 as well as CD80/class II were significantly decreased as compared to untreated 6-month-old control MRL-*Fas^lpr* mice. *p < 0.05 compared to untreated 6-month-old control MRL-*Fas^lpr* mice. FR: FR167653; v: vessel.

Figure 4. (a, b) CD11c-positive cells were detected in the T cell area in spleens from MRL-*Fas^lpr* mice. (c) CCR7-positive cells were located in the same lesions as CD11c-positive cells. (d) Cells dual-positive for CD11c and CCR7 were detected in the T cell area. Spleen pathology was determined by staining with the indirect avidin-biotinylated peroxidase complex method and dual-labeled immunofluorescence immunohistochemistry method (magnification: a ×100; b–d ×200). (e) In treated MRL-*Fas^lpr* mice, the number of CD11c-positive cells tended to decrease, but the differences compared to untreated mice were not significant. The numbers of mature dendritic cells dual-positive for CD11c and CCR7 as well as CD80/class II were significantly decreased compared to untreated MRL-*Fas^lpr* mice at 6 months of age. *p < 0.05 compared to untreated 6-month-old control MRL-*Fas^lpr* mice. FR: FR167653.

tively; Figure 6c, 6d). In addition, HMGB-1 staining was also detected in the T cell area of spleens from MRL-*Fas^lpr* mice, and this was reduced by p38 MAPK inhibition (data not shown).

HMGB-1 transcript levels were reduced in kidneys from treated MRL-Fas^lpr mice. Real-time RT-PCR was used to determine the mRNA levels of HMGB-1 in the whole kidney. In kidneys of treated MRL-*Fas^lpr* mice, HMGB-1 transcript levels were reduced compared to untreated controls (Figure 6e).

Both CD11c-positive cells and HMGB-1-positive areas were colocalized in diseased kidney and spleen from MRL-Fas^lpr mice. It has been reported that mature DC secrete

HMGB-1 via p38 MAPK activation[16,17]. Dual-labeling immunohistochemistry was performed to examine the effects of FR on the expression of HMGB-1 on CD11c-positive cells. Both CD11c-positive cells and HMGB-1-positive areas were colocalized in perivascular lesions in the diseased kidney at 6 months of age (Figure 6f). Some CD11c-positive cells were also positive for HMGB-1. The numbers of dual-positive cells were significantly decreased by inhibition of p38 MAPK compared to untreated controls (0.3% ± 0.0% and 0.8% ± 0.1%, respectively; p < 0.05; Figure 6g). In the spleen, cells dual-positive for CD11c and HMGB-1 were located in the T cell area (Figure 6h). The number of dual-positive cells was also reduced in the spleen of MRL-*Fas^lpr* mice compared to untreated controls (3.1% ± 0.1%, 4.2% ± 0.3%, respectively; p < 0.05; Figure 6i).

*Maturation of DC was inhibited by administration of*

Figure 5. (a) The percentage of CD11c-positive cells was analyzed by flow cytometry; results of representative experiments are shown. (b) In treated mice, the number of CD11c-positive cells in the circulation were significantly decreased compared to untreated 6-month-old control MRL-*Fas^lpr* mice. *p < 0.05 compared to untreated 6-month-old control MRL-*Fas^lpr* mice. FR: FR167653.

FR167653. In GM-CSF-derived bone marrow DC, stimulation with TNF-α increased the frequency of phosphorylated p38 MAPK-positive CCR7-positive phenotype as compared to control DC (42.0% ± 0.7%, 33.0% ± 1.6% in MRL-*Fas^lpr* mice; 66.3% ± 6.1%, 46.8% ± 6.2% in MRL++ mice, respectively; p < 0.05). In contrast, inhibition of p38 MAPK signaling decreased the frequency of phosphorylated p38 MAPK-positive CCR7-positive DC as compared to TNF-α-treated DC in each group (21.9% ± 3.2% in MRL-*Fas^lpr* mice, 31.5% ± 0.3% in MRL++ mice; p < 0.05; Figure 7a, 7b, 7c). In addition, FR treatment also decreased the number of phosphorylated p38 MAPK-positive class II-positive DC as compared to TNF-α-treated DC (29.1% ± 1.5%, 43.4% ± 1.5% in MRL-*Fas^lpr* mice; 35.8% ± 1.3%, 58.3% ± 13.4% in MRL++ mice, respectively; p < 0.05; Figure 7d).

Concentrations of HMGB-1, IL-12, and IL-23 in supernatants of cultured DC were reduced by FR167653 treatment. In cultured DC, TNF-α stimulation enhanced HMGB-1, IL-12, and IL-23 levels in the supernatants. However, the enhanced concentrations of these cytokines were reduced by treatment with FR in cultured DC from MRL-*Fas^lpr* mice as well as MRL++ mice (Figure 7e, 7f, 7g).

DISCUSSION

Our results suggested that DC are involved in the progression of autoimmune kidney diseases in MRL-*Fas^lpr* mice, followed by secretion of HMGB-1 via p38 MAPK activation. In the diseased kidney in particular, the numbers of CD11c-positive cells, including those with the mature phenotype, were reduced in treated mice. Interestingly, the number of CD11c-positive cells in circulation was decreased in accord with disease activity. HMGB-1 protein and transcripts were detected in the diseased kidney, and both were decreased by administration of FR167653. Moreover, CD11c-positive cells were located adjacent to the HMGB-1-positive area in the diseased kidney as well as the spleen. The number of dual-positive cells was reduced by inhibition of p38 MAPK. Maturation of DC and increased HMGB-1, IL-12, and IL-23 concentrations, induced by stimulation with TNF-α, were inhibited by FR167653 treatment *in vitro*. Therefore, we considered DC were involved in progression of autoimmune diseases in MRL-*Fas^lpr* mice, followed by production of cytokines, including HMGB-1, via p38 MAPK activation.

It has been reported that immature DC differentiate into mature DC, which show upregulation of CCR7 to migrate to

Figure 6. (a) High levels of HMGB-1 expression were observed within the glomeruli as well as mononuclear cell infiltrates in the interstitium. Kidney pathology was determined by staining with the indirect avidin-biotinylated peroxidase complex method (original magnification ×400). (b) HMGB-1-positive area was also detected in perivascular lesions in the diseased kidneys (original magnification ×200). (c, d) The percentage of HMGB-1-positive area was significantly decreased in glomeruli as well as the interstitium in FR-treated MRL-Fas[lpr] mice as compared to untreated 6-month-old control MRL-Fas[lpr] mice. (e) mRNA levels of HMGB-1 in the whole kidney were analyzed using real-time RT-PCR. In the kidneys of FR-treated MRL-Fas[lpr] mice, HMGB-1 transcript levels were reduced as compared to untreated 6-month-old control MRL-Fas[lpr] mice. (f) CD11c-positive cells and HMGB-1-positive area were colocalized in perivascular lesions in the diseased kidneys at 6 months of age. Some CD11c-positive cells were also positive for HMGB-1 (arrowheads). Kidney pathology was determined by staining with the indirect avidin-biotinylated alkaline phosphatase method for CD11c, with the indirect Envision peroxidase complex method for HMGB-1 (original magnification ×400). (g) Numbers of dual-positive cells in the diseased kidney were significantly decreased by inhibition of p38 MAPK. (h) In the spleen, cells dual-positive for CD11c and HMGB-1 were located in the T cell area (original magnification ×100). (i) Number of dual-positive cells in the spleen of treated MRL-Fas[lpr] mice was also reduced compared to untreated 6-month-old control MRL-Fas[lpr] mice. *$p < 0.05$ compared to untreated 6-month-old control MRL-Fas[lpr] mice.

regional lymph nodes via secondary lymphoid-tissue chemokine/CCR7 interaction[23,24]. It has been established that mature DC migrate toward regional lymph nodes,

where they interact with T cells. Previous studies indicated that maturation of DC induces autoimmune responses in mouse models[25-27]. These reports suggested that mature DC may play an important role in the pathogenesis of autoimmune diseases.

Our findings indicated that the p38 MAPK pathway is critical for the maturation of immature DC. Similarly, stimuli such as TNF-α, LPS, or contact sensitizers induced maturation of DC via p38 MAPK activation[3]. In our experiment, it should be noted that the inhibition of p38 MAPK reduced the number of mature DC in the diseased kidney and spleen. In support of this, the blockade of p38 MAPK has been shown to inhibit maturation of DC[3]. p38 MAPK has been reported to regulate the expression of CCR7 and migration of maturing DC to macrophage inflammatory protein-3ß and secondary lymphoid chemokines[28]. Further, DC from peripheral blood and spleen in a murine lupus model were shown to be chemoattracted toward secondary lymphoid chemokines[29]. Moreover, in acute lung inflammation models, mature DC were detected in the injured lung[30]. In this study, anti-secondary lymphoid chemokine antibody injection increased the number of DC within the injured lung, thus exacerbating pulmonary inflammation. These observations may explain our findings that the inhibition of p38 MAPK prevents not only maturation but also migration of DC from peripheral organs, resulting in improving autoimmune kidney diseases in our model.

p38 MAPK is involved in regulation of the expression of many proinflammatory cytokines[31]. Therefore, reduction of mature DC would partly be due to the reduction of microenvironmental stimuli, such as proinflammatory cytokines. Moreover, reduction of the total number of DC could reduce the number of cells with the mature phenotype. In addition, we noted that DC in circulation were reduced in accord with disease activity. These findings suggest that inhibition of p38 MAPK activation induces systemic reduction of DC in MRL-*Fas[lpr]* mice.

Recent studies showed that HMGB-1, which is released or secreted from necrotic cells, activated Mφ, and mature DC, possesses inflammatory properties[10]. HMGB-1 acts as an alarmin, a class of molecules that activate antigen-presenting cells and enhance the development of immune responses[11,12]. It has been reported that HMGB-1 is expressed in various tissues, such as synovial tissue, from patients with rheumatoid arthritis[14], liver tissues from hepatitis models[32], and some tumor cells[10]. Our findings suggest that HMGB-1, which may be secreted from mature DC through p38 MAPK activation, plays a role in the pathogenesis of autoimmune kidney diseases. Mature DC secrete HMGB-1, which is crucial for the signal transduction events that maintain DC maturation and for the control of T cell function[16]. Further, HMGB-1 induced phenotypic maturation of immature DC. Messmer, *et al* reported that HMGB-1 induced DC maturation and secretion of proinflammatory

Figure 7. (a–d) Stimulation with TNF-α increased the frequency of phosphorylated p38 MAPK-positive CCR7-positive phenotype compared to control dendritic cells. Inhibition of p38 MAPK signaling decreased the frequency of phosphorylated p38 MAPK-positive CCR7-positive dendritic cells as well as phosphorylated p38 MAPK-positive class II-positive dendritic cells. (e, f, g) In cultured dendritic cells, TNF-α stimulation enhanced HMGB-1, IL-12, and IL-23 levels in the supernatants. Increased concentrations of these cytokines were decreased by treatment with FR167653. ++ $p < 0.05$ compared to controls; * $p < 0.05$ compared to TNF-α-stimulated group.

cytokines, such as IL-1ß and TNF-α[17]. In that report, maturation of DC induced by HMGB-1 was shown to be dependent on p38 MAPK activation, using the p38 MAPK inhibitor. These results raise the possibility that HMGB-1 contributes to the maturation of DC in an autocrine-paracrine loop.

In addition, the stimulation of TNF-α induced the secretion of IL-12 and IL-23 as well as HMGB-1 *in vitro*, which was reduced by inhibition of p38 MAPK. DC have been reported to promote production of IL-17 by CD4-positive T cells via secretion of IL-12 and IL-23[33]. These results raise the possibility that DC play an important role in activation of the Th17 pathway in this model. However, more detailed studies are needed to determine the association between DC and the Th17 pathway in this model.

We observed that CD11c-positive cells are involved in autoimmune kidney injury in MRL-*Fas^lpr* mice. Our results indicated that dendritic cells secrete HMGB-1 through p38

MAPK activation to participate in autoimmunity in this model.

REFERENCES
1. Quah BJ, O'Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005;9:643-54.
2. Flores-Romo L. In vivo maturation and migration of dendritic cells. Immunology 2001;102:255-62.
3. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers. J Immunol 2001;166:3837-45.
4. Xie J, Qian J, Wang S, Freeman ME 3rd, Epstein J, Yi Q. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol 2003;171:4792-800.
5. Hardin JA. Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann Rheum Dis 2005;64 Suppl 4:iv86-90.
6. Nelson PJ. Renal ischemia-reperfusion injury: Renal dendritic cells loudly sound the alarm. Kidney Int 2007;71:604-5.
7. Eijgenraam JW, Woltman AM, Kamerling SW, et al. Dendritic cells

Iwata, et al: Dendritic cells and lupus

of IgA nephropathy patients have an impaired capacity to induce IgA production in naive B cells. Kidney Int 2005;68:1604-12.

8. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int 2005;68:1096-108.

9. Kruger T, Benke D, Eitner F, et al. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 2004;15:613-21.

10. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36-42.

11. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005;17:359-65.

12. Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins initiate host defense. Adv Exp Med Biol 2007;601:185-94.

13. Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48:971-81.

14. af Klint E, Grundtman C, Engstrom M, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum 2005;52:3880-9.

15. Ek M, Popovic K, Harris HE, Nauclér CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006;54:2289-94.

16. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005;174:7506-15.

17. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307-13.

18. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol 1999;19:57-66.

19. Iwata Y, Wada T, Furuichi K, et al. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol 2003;14:57-67.

20. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006;103:14098-103.

21. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.

22. Fujikado N, Saijo S, Yonezawa T, et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 2008;14:176-80.

23. Gwendalyn JR, Guzman SS, Veronique A. Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunol 2005;26:273-87.

24. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447-50.

25. Bondanza A, Zimmermann VS, Dell'Antonio G, et al. Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J Immunol 2003;170:24-7.

26. Mehling A, Loser K, Varga G, et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001;194:615-28.

27. Chen M, Wang Y-H, Wang Y, Woolley AT, Farnsworth PB, Lee ML. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006;311:1160-4.

28. Ardeshna KM, Pizzey AR, Walker SJ, Devereux S, Khwaja A. The upregulation of CC chemokine receptor 7 and the increased migration of maturing dendritic cells to macrophage inflammatory protein 3ß and secondary lymphoid chemokine is mediated by the p38 stress-activated protein kinase pathway. Br J Haematol 2002;119:826-9.

29. Ishikawa S, Nagai S, Sato T, et al. Increased circulating CD11b+ CD11c+ dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-a into BLC/CXCL-13 producing DC. Eur J Immunol 2002;32:1881-7.

30. Itakura M, Tokuda A, Kimura H, et al. Blockade of secondary lymphoid tissue chemokine exacerbates Propionibacterium acnes-induced acute lung inflammation. J Immunol 2001;166:2071-9.

31. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7.

32. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-43.

33. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008;19:41-52.